- Critical care
- Ear, Nose and Throat
- Infectious Diseases
- Mental Health
- Metabolic and Endocrine
- Musculoskeletal Health
- Neuroprogressive and Dementia
- Oral and Dental
- Primary Care
- Regenerative Medicine
- Reproductive Health and Childbirth
- Trauma and Emergencies
The Cancer Network supports a wide range of clinical studies which are helping to progress cancer care in Scotland and beyond and all Scottish research ongoing within the network is registered with the National Institute of Health Research (NIHR). The cancer clinical trial portfolio is very dynamic and is frequently changing as studies open and close to recruitment. Across Scotland, there is a wide range of clinical trials happening in different disease sites. Information on trials happening in the UK can be found on the UK Clinical Trials Gateway and the Cancer Research UK website. For specific information on trials happening in Scotland please contact your cancer professional or your local cancer research network.
To highlight the clinical trials happening in Scotland the cancer research network will feature current trials happening during the different cancer awareness months that take place throughout the year.
Tuesday 4 February is World Cancer Day - read more
February: Oesophageal Cancer Awareness Month
Oesophageal cancer is a type of cancer affecting the oesophagus (gullet) – the long tube that carries food from the throat to the stomach. Cancers in the upper part and middle part of the oesophagus tend to be squamous cell carcinomas. These develop from cells that make up the inner lining of your oesophagus. Cancers in the lower part of the oesophagus tend to be a type called adenocarcinoma. These cancers start in gland cells. Oesophageal cancer is more common in older people and more common in men than women. It's the thirteenth most common cancer in the UK.
For more information on oesophageal cancer please visit Cancer Research UK.
The OCCAMS trial is determining predictive and prognostic biomarkers and therapeutic targets for oesophageal cancer and cancer that occur at the junction between the oesophagus and stomach. This will be done using whole-genome sequencing. The trial will look at patients at the beginning of their cancer treatment. Patients will receive the normal cancer treatments available in current practice and this new system will run in parallel to determine how practical it is compared to current practice. The trial will also look at molecular survival predictions that the new system can provide.
This trial is recruiting patients in Edinburgh, Dundee and Kilmarnock.
SCOPE 2 is a randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemoradiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET).
In lay terms, this means that the trial is looking at a higher than normal dose of radiotherapy and a different type of chemotherapy to treat oesophagus cancer. SCOPE 2 is recruiting in Aberdeen, Glasgow and Inverness and will soon be open in Dundee.
Spotlight is a Phase III study of Zolbetuximab + mFolfox compared with Placebo Plus mFOLFOX6 for patients with Locally Advanced inoperable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. The study will be looking at the efficacy of using a new treatment Zolbetuximab, they will also study the overall survival rates of the patients and the types of side effects.
SPOTLIGHT is recruiting in Aberdeen and Edinburgh.